B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target

Ovid reported Q4 2025 EPS of $0.06 vs consensus -$0.1137 (152.77% surprise) and revenue $718k vs $80.67k expected (+790.05%). B. Riley reiterated a Buy with a $5.00 target and Leerink Partners reiterated Outperform/$5.00; the stock has surged 434% over the past year and trades at $2.30 (market cap ~$300M). The company holds ~$150M pro forma cash with a runway into 2029, and provided development timelines: OV329 pediatric Phase 2 (60 subjects, 8-week study, results ~mid-2027), an open-label PPR study (12–20 subjects starting Q3 2026, results likely Q4 2026), an enhanced ketamine qEEG challenge, a KCC2 R&D Day on Apr 14, 2026, and OV4071 Phase 1 on track for Q2 2026.

Analysis

A clinical program that meaningfully reduces binary safety uncertainty typically shifts investor focus from peak sales scenarios to pathway-to-market mechanics: payer segmentation for pediatric neurology, pediatric formulation adoption curves, and longevity of patient retention. That re-rating is not linear — successful de-risking often unlocks a near-term rerating (multiple expansion) followed by a mid-term valuation reset driven by commercial assumptions (penetration, duration, price) rather than just trial success probability.

Second-order winners include pediatric formulation CDMOs, CROs with pediatric neurology expertise, and larger oncology/rare-disease acquirers seeking platform breadth; losers are small competitors without pediatric formulations who now face a higher bar for differentiation. Additionally, broader validation of a novel mechanism increases M&A optionality for platform owners, but it also tightens investigator/CRO capacity, which can elongate timelines and push up study costs.

Key event and model risks live on a 6–18 month horizon: mechanistic challenge readouts and early phase proof-of-concept are high-volatility binary events that can both compress and expand implied volatility rapidly. Downside triggers include inconsistent surrogate signals (e.g., qEEG mismatch), payer skepticism about pediatric pricing, or a need to partner/dilute to fund pivotal programs — each flips the rerating quickly.

For positioning, prefer structures that capture asymmetric upside to a successful de-risking while limiting premium paid to fast-decaying, near-term volatility. The highest expected ROI is from owning optionality through multi-quarter expiries or event-hedged equity exposure; the cheapest hedge is a narrow put spread sized to limit catastrophic drawdown without blocking upside appreciation.

Key Decisions for Investors

• Long OVID via calendar or diagonal call spread (buy 12–18 month LEAP, sell nearer-term call 3–4 months out after any press release spike). Timeframe: 6–18 months to capture de-risking and re-rate. Risk/reward: max loss = premium paid (limit 1–2% portfolio), upside asymmetry if program reads positive; reduces theta bleed vs buying short-dated calls.
• Event-hedged equity: buy OVID stock sized at 0.5–1% portfolio paired with a 4–6% notional short position in XBI (or IBB) to isolate idiosyncratic catalyst risk. Timeframe: 6–12 months. Risk/reward: preserves upside from successful readouts while cutting sector beta; keep stop-loss on net position if biotech index drops >15% to control systemic risk.
• Volatility arbitrage if IV spikes post-announcement: sell a 1–2 month call spread and buy a 6–12 month call (reverse calendar) to monetize short-term IV while keeping long-dated upside. Timeframe: trade around press releases. Risk/reward: collect near-term premium to offset long leg cost; cap upside sold by spread width — suitable when short-term IV > long-term IV.
• Contrarian downside hedge: buy a 3–6 month put spread if implied success probability appears >40–50% (market pricing). Timeframe: tactical (weeks–months) into next catalyst. Risk/reward: limited, defined loss (premium) with meaningful payoff if any early signal disappoints; size as portfolio insurance (0.5% exposure).